Important characteristics of the derivation and validation cohorts
| Characteristics | Derivation cohort (N=945) | Validation cohort (N=177) | P value |
| Baseline characteristics | |||
| Male, n (%) | 605 (64.02) | 122 (68.93) | 0.21 |
| Age, mean±SD, years | 64.92±12.18 | 64.04±12.73 | 0.38 |
| NIHSS, median (IQR) | 15 (11–21) | 14 (10–17) | 0.01 |
| Medical history, n (%) | |||
| Diabetes | 209 (22.12) | 41 (23.16) | 0.76 |
| Hypertension | 538 (56.93) | 104 (58.76) | 0.65 |
| Stroke/TIA | 179 (18.94) | 41 (23.16) | 0.19 |
| Atrial fibrillation | 79 (8.36) | 26 (14.69) | 0.01 |
| Current smoke | 335 (35.52) | 66 (37.29) | 0.65 |
| IVT, n (%) | 281 (29.74) | 56 (31.64) | 0.61 |
| Occlusion location | |||
| ICA | 253 (26.77) | 36 (20.34) | 0.07 |
| ACA | 15 (1.59) | 5 (2.82) | 0.25 |
| MCA | 479 (50.69) | 74 (41.81) | 0.03 |
| VA | 84 (8.89) | 7 (3.95) | 0.03 |
| BA | 151 (15.98) | 16 (9.04) | 0.02 |
| PCA | 18 (1.90) | 2 (1.13) | 0.47 |
| Time intervals, median (IQR), min | |||
| Onset to door | 186 (97–346) | 204 (110–300) | 0.01 |
| Onset to recanalisation | 480 (344–658) | 472 (351–640) | 0.44 |
| Passes, n (%) | 0.32 | ||
| <3 | 593 (62.75) | 118 (66.67) | |
| ≥3 | 352 (47.25) | 59 (33.33) | |
| Post-EVT mTICI, n (%) | 0.75 | ||
| 2b | 278 (29.42) | 50 (28.25) | |
| 3 | 667 (70.58) | 127 (71.75) | |
| 24 hours follow-up, median (IQR) | |||
| 24 hours GCS | 11 (7–14) | 11(7–15) | 0.77 |
| 24 hours NIHSS | 13 (7–19) | 13 (6–18) | 0.71 |
| Infarct volume at 24 hours, mL | 20.31 (6.82–60.38) | 26.65 (8.91–97.90) | 0.10 |
| mRS 3–6 at 90 days, n (%) | 510 (53.97) | 107 (60.45) | 0.11 |
ACA, anterior cerebral artery; BA, basilar artery; EVT, endovascular treatment; GCS, Glasgow Coma Scale; ICA, internal carotid artery; IVT, intravenous thrombolysis; MCA, middle cerebral artery; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral artery; TIA, transient ischaemic attacks; VA, vertebral artery.